HIGH RESISTANCE INDICATIONS and Pipeline
Agressive Lymphoma
15% Primary Refractory
15-25% Acquired Resistance
Multi-Center Clinical Study Results Published
Pancreatic Cancer
(PDAC)
~80–85% Resistance
(Near-universal)
High-grade
Ovarian cancer
25% Primary Platinum Resistant
22% Acquired Platinum Resistance
Lungs
(NSCLC)
5-30% Primary Resistance
60-70% Acquired Resistance
POC Clinical Study Results
To be Published Soon
Breast Cancer
(TNBC)
40–50% Primary Resistance 30–50% Acquired Resistance
Glioblastoma & Glioma
High intrinsic resistance and rapid acquired resistance
Colon
(mCRC)
15-30% Primary Resistance
50-90% Acquired Resistance
POC Clinical Study
HER2+ Gastric Cancer
50% Primary Resistance
30–50% Secondary
Hepatocellular carcinoma
Resistance - Common
AGGRESSIVE LYMPHOMA
LYMPHOMA CURRENT STANDARD OF CARE
Lymphoma, the fifth most prevalent hematologic malignancy, is predominantly managed using PET/CT imaging for staging and treatment response assessment.
PET/CT, though informative, captures discrete metabolic snapshots rather than subclinical activity, often creating a critical metabolic window in which imaging normalization may mask persistent underlying disease.
Patients with unidentified refractory disease face compounding consequences: ongoing tumor progression, T-cell exhaustion, and diminished efficacy of subsequent therapies such as CAR-T - ultimately impacting overall survival.
While ctDNA has emerged as a blood-based tool for detecting minimal residual disease, it reflects tumor-derived genomic burden alone and fails to capture the functional tumor–host interactions that underlie immune evasion and disease advancement.
AGGRESSIVE LYMPHOMA CLINICAL VALIDATION
A Three-year Multi-center Clinical study demonstrated that longitudinal intra-patient FGL2 prothrombinase activity accurately and robustly discriminates treatment response and sustained remission from disease progression or active clinical disease, achieving an AUC of 0.91 (95% CI) - with further enhanced discriminatory performance observed in treatment resistant patients (AUC 0.94).
LUNG CANCER
LUNG CANCER - CURRENT STANDARD OF CARE
Current standards rely on imaging like CT scans every 6-12 weeks for initial monitoring and every 6 months thereafter to assess treatment response in lung cancer, particularly NSCLC. This approach follows RECIST criteria to measure tumor size changes but lacks the frequency needed for ongoing surveillance.
While effective for baseline evaluations, it often misses early signs of disease progression or treatment resistance, delaying critical adjustments to therapy.
Patients face risks from undetected resistance, highlighting the urgent need for more frequent, non-invasive monitoring to track progression in real time and improve outcomes.
